Policy & Regulation
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
13 November 2026 - Rezolute, Inc. (NASDAQ: RZLT), a late-stage metabolic disease company focused on treating refractory hypoglycemia caused by hyperinsulinism, said preliminary results from a data eva...
Eisai launches subcutaneous Leqembi Pen in Japan for early Alzheimer's disease
13 November 2026 - Swedish research-based biopharma company BioArctic AB (STO: BIOA-B) on Friday said its Japanese partner Eisai Co Ltd (TYO: 4523) has launched Leqembi Pen, the subcutaneous formulati...
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
13 November 2026 - New York-based global type 1 diabetes (T1D) research and advocacy organisation Breakthrough T1D and the Walgreens Foundation announced on Thursday a new national partnership support...
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
13 November 2026 - Innovent Biologics, Inc. (HKEX: 01801), a China-based biopharmaceutical company that develops, manufactures, and commercialises medicines for the treatment of oncology, autoimmune, ...
FDA grants Breakthrough Therapy designation to Clarity Pharmaceuticals' prostate cancer imaging agent
12 November 2026 - Australian clinical-stage radiopharmaceutical company Clarity Pharmaceuticals Ltd (ASX: CU6) said on Thursday the US Food and Drug Administration (FDA) has granted Breakthrough Ther...
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme
12 November 2026 - Clinical-stage biopharmaceutical company Traws Pharma, Inc. (NASDAQ: TRAW) on Thursday reported final results from a 92-patient Phase 2a study of ratutrelvir, its investigational on...